[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334849-105":59,"doc-detail-334849-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","deep-learning-model-for-tumor-type-prediction-using-targeted-clinical-genomic-sequencing-data","Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data","","Tumor type is essential for cancer care, yet histology-based diagnosis can remain uncertain, especially in poorly differentiated tumors or cancers of unknown primary. Genomic alterations carry strong tumor-type signals, but prior classifiers can be limited by whole-genome/whole-exome feature requirements or restricted cancer scope. This work trains a hyperparameter ensemble, GDD-ENS, using targeted clinical cancer gene panel data from 39,787 solid tumors to classify 38 cancer types.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deep-learning-model-for-tumor-type-prediction-using-targeted-clinical-genomic-sequencing-data/334849/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deep-learning-model-for-tumor-type-prediction-using-targeted-clinical-genomic-sequencing-data/334849.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is tumor-type diagnosis difficult in clinical practice?","Question",{"text":112,"@type":113},"Histology and IHC analyses can be inconclusive for poorly differentiated tumors and for distinguishing independent primaries from clonally related metastases. For cancers of unknown primary, the tissue of origin is unknown, which limits diagnostic guidance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data and model does the study use for tumor-type classification?",{"text":117,"@type":113},"The approach uses genomic features from 39,787 solid tumors sequenced with a clinically targeted cancer gene panel. It trains a Genome-Derived-Diagnosis Ensemble (GDD-ENS) built as a hyperparameter ensemble of deep neural networks.",{"name":119,"@type":110,"acceptedAnswer":120},"What performance and clinical coverage does GDD-ENS achieve?",{"text":121,"@type":113},"GDD-ENS reaches 93% accuracy for high-confidence predictions across 38 cancer types, comparable to WGS-based methods. It is also intended to help with rare tumor types and cancers of unknown primary, and can incorporate patient-specific clinical information for improved predictions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334849,1790022877,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","RESEARCH ARTICLE  \nDeep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data   \nMadison Darmofal1,2, Shalabh Suman3, Gurnit Atwal4,5,6, Michael Toomey1,2, Jie-Fu Chen3, Jason C. Chang3, Efsevia Vakiani3, Anna M. Varghese7, Anoop Balakrishnan Rema3, Aijazuddin Syed3, Nikolaus Schultz8,9,10, Michael F. Berger3,8,9, and Quaid Morris1  \nABSTRACT  Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis remains challenging. Genomic alterations are highly diagnostic of tumor type,  \nand tumor-type classifiers trained on genomic features have been explored, but the most accurate methods are not clinically feasible, relying on features derived from whole-genome sequencing (WGS), or predicting across limited cancer types. We use genomic features from a data set of 39,787 solid tumors sequenced using a clinically targeted cancer gene panel to develop Genome-Derived-Diagnosis Ensemble (GDD-ENS): a hyperparameter ensemble for classifying tumor type using deep neural networks. GDD-ENS achieves 93% accuracy for high-confidence predictions across 38 cancer types, rivaling the performance of WGS-based methods. GDD-ENS can also guide diagnoses of rare type and cancers of unknown primary and incorporate patient-specific clinical information for improved predictions. Overall, integrating GDD-ENS into prospective clinical sequencing workflows could provide clinically relevant tumor-type predictions to guide treatment decisions in real time.  \nSIGNIFICANCE: We describe a highly accurate tumor-type prediction model, designed specifically for clinical implementation. Our model relies only on widely used cancer gene panel sequencing data, predicts across 38 distinct cancer types, and supports integration of patient-specific nongenomic information for enhanced decision support in challenging diagnostic situations.  \nSee related commentary by Garg, p. 906.  \nINTRODUCTION  \nKnowledge of a patient’s tumor type is crucial for clinical decision-making in cancer, guiding therapy choice, and clinical trial enrollment. Tumor-type diagnosis is typically performed via histologic and IHC analyses, but these techniques may be inconclusive, especially ifa patient’s tumor is poorly differentiated, or when distinguishing between independent primary tumors or clonally related metastases. For cancers of unknown primary (CUP), which account for 3% to 5% of patients diagnosed in the United States today or 60,000 to 100,000 cases per year, the true tissue of origin is unknown and unable to guide  \n1Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York. 2Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, New York. 3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 4Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada. 5Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. 6Vector Institute, Toronto, Ontario, Canada. 7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.  \n8Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 9Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 10Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.  \nM.F. Berger and Q. Morris jointly supervised this article.  \nCorresponding Authors: Quaid Morris, Computational and Systems Biology Program, Sloan Kettering Institute, 417 East 68th Street, New York City, [NY 10065. E-mail: morrisq@mskcc.org](NY 10065. E-mail: morrisq@mskcc.org); and Michael Berger, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, New York City,  \nNY 10065. E-mail: [bergerm1@mskcc.org](bergerm1@mskcc.org)  \nCancer Di","cbCairugdkDW5hny","https://ap.wps.com/l/cbCairugdkDW5hny","pdf",7429519,18,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"Why is tumor-type diagnosis difficult in clinical practice?\",\"answer\":\"Histology and IHC analyses can be inconclusive for poorly differentiated tumors and for distinguishing independent primaries from clonally related metastases. For cancers of unknown primary, the tissue of origin is unknown, which limits diagnostic guidance.\"},{\"question\":\"What data and model does the study use for tumor-type classification?\",\"answer\":\"The approach uses genomic features from 39,787 solid tumors sequenced with a clinically targeted cancer gene panel. It trains a Genome-Derived-Diagnosis Ensemble (GDD-ENS) built as a hyperparameter ensemble of deep neural networks.\"},{\"question\":\"What performance and clinical coverage does GDD-ENS achieve?\",\"answer\":\"GDD-ENS reaches 93% accuracy for high-confidence predictions across 38 cancer types, comparable to WGS-based methods. It is also intended to help with rare tumor types and cancers of unknown primary, and can incorporate patient-specific clinical information for improved predictions.\"}]","Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data | PDF",1790008569,45]